Literature DB >> 7262023

Response of rat ventral prostate to a new and novel 5 alpha-reductase inhibitor.

J R Brooks, E M Baptista, C Berman, E A Ham, M Hichens, D B Johnston, R L Primka, G H Rasmusson, G F Reynolds, S M Schmitt, G E Arth.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7262023     DOI： 10.1210/endo-109-3-830

Source DB:  PubMed          Journal:  Endocrinology        ISSN： 0013-7227            Impact factor:   4.736


× No keyword cloud information.
  6 in total

1.  Consideration of the use of 17 beta-N,N-diethylcarbamoyl-4-methyl-4-aza-5- alpha-androstan-3-one (4MA), a 5 alpha-reductase inhibitor, in prostate cancer therapy.

Authors:  A A Geldof; M F Meulenbroek; I Dijkstra; S Bohlken; B R Rao
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

2.  Structural and biochemical properties of cloned and expressed human and rat steroid 5 alpha-reductases.

Authors:  S Andersson; D W Russell
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

3.  Pharmacokinetics and biochemical efficacy after single and multiple oral administration of N-(2-methyl-2-propyl)-3-oxo-4-aza-5 alpha-androst-1-ene-17 beta-carboxamide, a new type of specific competitive inhibitor of testosterone 5 alpha-reductase, in volunteers.

Authors:  M Ohtawa; H Morikawa; J Shimazaki
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1991 Jan-Mar       Impact factor: 2.441

4.  Deletion of steroid 5 alpha-reductase 2 gene in male pseudohermaphroditism.

Authors:  S Andersson; D M Berman; E P Jenkins; D W Russell
Journal:  Nature       Date:  1991-11-14       Impact factor: 49.962

Review 5.  Role of 5 alpha-reductase inhibitors in the management of prostate cancer.

Authors:  Steven J Hudak; Javier Hernandez; Ian M Thompson
Journal:  Clin Interv Aging       Date:  2006       Impact factor: 4.458

6.  The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels.

Authors:  R J Cote; E C Skinner; C E Salem; S J Mertes; F Z Stanczyk; B E Henderson; M C Pike; R K Ross
Journal:  Br J Cancer       Date:  1998-08       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.